An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
Sobha Sivaprasad,1 Richard C Browning,2 Carla Starita2 1Consultant Ophthalmologist, King’s College Hospital, Denmark Hill, London, 2Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, UK Background: The purpose of this study was to evaluate the safety and tolerability of pegaptanib...
Guardado en:
Autores principales: | Sivaprasad S, Browning RC, Starita C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a1de79aa784744a59b289c87bbf37da0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire CA, et al.
Publicado: (2015) -
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
por: Udaondo P, et al.
Publicado: (2011) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sobha Sivaprasad
Publicado: (2008) -
Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema
por: Basile AS, et al.
Publicado: (2015) -
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sobha Sivaprasad, et al.
Publicado: (2008)